Analyst sees Invesco Pharmaceuticals ETF as a long-term or tactical option; it beat XLV in the past year but lagged from July 2015 to July 2025.
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be reporting results this Monday morning. Here’s what to look for.
About This EventJazz Pharmaceuticals (Nasdaq: JAZZ), a global biopharma company whose purpose is to innovate to transform the lives of patients and their families, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, Renee Gala, President and Chief Executive Officer, rings the Closing Bell.
Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.
Jazz Pharmaceuticals entered this earnings season trading like a problem child with potential, well below many fair value models and still dealing with the memory of a large one off loss. Q2 2026 results landed with a jolt. The stock rose 7.2% in regular trading to US$229.97 as investors reacted to a mix of strong Q3 revenue of US$1.24b and a much cleaner trailing earnings picture at 12 month basic earnings per share of US$15.25. Like the cleaner earnings profile at Jazz Pharmaceuticals but...
Jazz Pharmaceuticals jumps after raising its 2026 revenue forecast and topping Q3 sales estimates. Read more here.
Jazz Pharmaceuticals (JAZZ) has an average rating of buy and mean price target of $299.81, according
Jazz (JAZZ) delivered earnings and revenue surprises of +5.13% and +2.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.
Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.
Jazz Pharmaceuticals' strategy is starting to pay dividends.
Jazz Pharmaceuticals is transforming beyond oxybate reliance, with growth across sleep medicine, epilepsy, and oncology portfolios. See why JAZZ stock is a Buy.
Jim Cramer backed the tumbling pharma stock, even though JAZZ shares have fallen during the past month.
Cramer warns against Apple Hospitality if rates hit 6%, prefers Vylor over Corteva, backs Jazz, and notes SpaceX may bid for EchoStar.
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Nuvation Bio NUVB) stock and Jazz Pharmaceuticals (JAZZ) stock gain as Citi issues new Buy ratings on the firms based on their cancer treatments. Read more here.
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.